Literature DB >> 28647091

Phenotypic screening-the fast track to novel antibody discovery.

Ralph R Minter1, Alan M Sandercock1, Steven J Rust2.   

Abstract

The majority of antibody therapeutics have been isolated from target-led drug discovery, where many years of target research preceded drug program initiation. However, as the search for validated targets becomes more challenging and target space becomes increasingly competitive, alternative strategies, such as phenotypic drug discovery, are gaining favour. This review highlights successful examples of antibody phenotypic screens that have led to clinical drug candidates. We also review the requirements for performing an effective antibody phenotypic screen, including antibody enrichment and target identification strategies. Finally, the future impact of phenotypic drug discovery on antibody drug pipelines will be discussed.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Mesh:

Substances:

Year:  2017        PMID: 28647091     DOI: 10.1016/j.ddtec.2017.03.004

Source DB:  PubMed          Journal:  Drug Discov Today Technol        ISSN: 1740-6749


  9 in total

1.  Chimeric Antigen Receptor Library Screening Using a Novel NF-κB/NFAT Reporter Cell Platform.

Authors:  Julian Rydzek; Thomas Nerreter; Haiyong Peng; Sabrina Jutz; Judith Leitner; Peter Steinberger; Hermann Einsele; Christoph Rader; Michael Hudecek
Journal:  Mol Ther       Date:  2018-11-20       Impact factor: 11.454

2.  FACS-Based Functional Protein Screening via Microfluidic Co-encapsulation of Yeast Secretor and Mammalian Reporter Cells.

Authors:  Desislava Yanakieva; Adrian Elter; Jens Bratsch; Karlheinz Friedrich; Stefan Becker; Harald Kolmar
Journal:  Sci Rep       Date:  2020-06-23       Impact factor: 4.379

3.  Deep Mining of Complex Antibody Phage Pools Generated by Cell Panning Enables Discovery of Rare Antibodies Binding New Targets and Epitopes.

Authors:  Anne Ljungars; Carolin Svensson; Anders Carlsson; Elin Birgersson; Ulla-Carin Tornberg; Björn Frendéus; Mats Ohlin; Mikael Mattsson
Journal:  Front Pharmacol       Date:  2019-07-30       Impact factor: 5.810

4.  Bispecific antibody target pair discovery by high-throughput phenotypic screening using in vitro combinatorial Fab libraries.

Authors:  Pallavi Bhatta; Kevin D Whale; Amy K Sawtell; Clare L Thompson; Stephen E Rapecki; David A Cook; Breda M Twomey; Milena Mennecozzi; Laura E Starkie; Emily M C Barry; Shirley J Peters; Ahmad M Kamal; Helene M Finney
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

Review 5.  Viro-antibody therapy: engineering oncolytic viruses for genetic delivery of diverse antibody-based biotherapeutics.

Authors:  Roland E Kontermann; Guy Ungerechts; Dirk M Nettelbeck
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

6.  Microenvironment mapping via Dexter energy transfer on immune cells.

Authors:  Jacob B Geri; James V Oakley; Tamara Reyes-Robles; Tao Wang; Stefan J McCarver; Cory H White; Frances P Rodriguez-Rivera; Dann L Parker; Erik C Hett; Olugbeminiyi O Fadeyi; Rob C Oslund; David W C MacMillan
Journal:  Science       Date:  2020-03-06       Impact factor: 47.728

Review 7.  Secretome-Based Screening in Target Discovery.

Authors:  Mei Ding; Hanna Tegel; Åsa Sivertsson; Sophia Hober; Arjan Snijder; Mats Ormö; Per-Erik Strömstedt; Rick Davies; Lovisa Holmberg Schiavone
Journal:  SLAS Discov       Date:  2020-05-19       Impact factor: 3.341

8.  A platform for phenotypic discovery of therapeutic antibodies and targets applied on Chronic Lymphocytic Leukemia.

Authors:  A Ljungars; L Mårtensson; I Teige; M Mattsson; J Mattsson; M Kovacek; A Sundberg; U-C Tornberg; B Jansson; N Persson; V Kuci Emruli; S Ek; M Jerkeman; M Hansson; G Juliusson; M Ohlin; B Frendéus
Journal:  NPJ Precis Oncol       Date:  2018-09-03

9.  Accelerating target deconvolution for therapeutic antibody candidates using highly parallelized genome editing.

Authors:  Jenny Mattsson; Ludvig Ekdahl; Fredrik Junghus; Ram Ajore; Eva Erlandsson; Abhishek Niroula; Maroulio Pertesi; Björn Frendéus; Ingrid Teige; Björn Nilsson
Journal:  Nat Commun       Date:  2021-02-24       Impact factor: 14.919

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.